Tokai Pharmaceuticals (Cambridge, MA) a clinical-stage pharmaceutical company focused on prostate cancer, closed a $23M Series D financing. Participants include Novartis Venture Fund and Apple Tree Partners.

Ambit Biosciences (San Diego, CA) a clinical-stage biopharmaceutical company focused on kinase inhibitors for the treatment of cancer and other conditions, closed a $30M Series D financing. Participants include Apposite Capital, Perseus-Soros Biopharmaceutical Fund, OrbiMed, Forward Ventures, Roche Venture Fund, MedImmune Ventures, Gimv, GrowthWorks, GeneChem, Radius Ventures and NovaQuest Capital Management.
The 2Q11 OnBioVC Trend Analysis [...]

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.
The 2Q11 OnBioVC Trend Analysis will be [...]

Esperance Pharmaceuticals (Baton Rouge, LA) a clinical-stage oncology and companion diagnostic company, closed a $7.5M Series B financing. Participants include Sanofi, Louisiana Fund, Themelios Ventures, Research Corporation Technologies and Advantage Capital Partners.

Cyterix Pharmacautics (San Francisco, CA) a preclinical-stage small molecule pharmaceutical company focused on oncology,closed a $9.2M Series A financing. Participants include the Column Group and SV Life Sciences.

Acetylon Pharmaceuticals (Boston, MA) a clinical-stage pharmaceuticals company focused on relapsed and relapsed-refractory multiple myeloma ,closed a $27M Series B financing. Participants have included New Spring Capital.

Q Chip (United Kingdom) a preclinical-stage biopharmaceutical company focused on sustained release formulations of oncology and endocrine therapeutics, closed a $6M Series C financing. Participants include Limburg Ventures and Nedermaas Hightech Ventures.

Oncofactor (Seattle, WA) a development stage biopharmaceutical company focused on oncology, closed a $2.1M Series A financing. Participants include Accelerator, OVP Venture Partners, Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners and WRF Capital.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage pharmaceutical company developing novel small molecule drugs to treat cancer, closed a $6M Series C financing bringing the total round to $43M. Participants include Nextech Invest, Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, Vertical Group and Amgen Ventures.

Taris Biomedical (Lexington, MA) a clinical-stage specialty pharmaceutical company focused on bladder diseases in pain, inflammation, oncology and incontinence, closed a $18.3M Series B financing. Participants include Third Rock Ventures, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners.

Blueprint Medicines (Cambridge, MA) a development-stage biopharmaceutical company focused on personalized cancer therapies, closed a $40M Series A financing. Participants include Third Rock Ventures.

Aslan Pharmaceuticals (Singapore) a clinical-stage pharmaceutical company focused on oncology, respiratory and inflammation, closed a $12M Series A financing. Participants include BioVeda Capital.

Aduro Biotech (Berkeley, CA) a clinical-stage therapeutic immunotherapy vaccine company focused on cancer and infectious disease, closed a $19.2M Series B financing. Participants include Morningside Ventures.